CEFTRIAXONE VERSUS CEFTAZIDIME PLUS AMINOGLYCOSIDE THERAPY FOR INFECTIONS IN PATIENTS WITH NEUTROPENIA AFTER CYTOTOXIC CHEMOTHERAPY

One hundred and one patients undergoing anticancer chemotherapy due to hematologic malignancy were retrospectively divided into two groups: 67 patients were treated with ceftriaxone plus amikacine, receiving on ce daily (od) 2-4 g ceftriaxone, 1-1.5 g amikacine (those without a pe ripheral or central venous catheter) and 34 patients with central or p eripheral venous catheter (CPVC) receiving ceftizidime 2 g three times daily (tid) plus amikacine 0.5 g tid iv. Both groups were similar as to their isolated pathogens, localization of infection, and basic diag noses of hematologic malignancies. There was no significant difference in efficacy between ceftriaxone plus amikacine versus ceftazidime plu s amikacine, but the toxicity was lower In once daily ceftriaxone plus amikacine group.